Servier: Committed to and with patients

At Servier, our commitment to therapeutic progress for the benefit of patients is at the heart of our mission. Like our organization – a foundation-governed laboratory – we invest over 20% of our revenue from brand-name medicinesannually in research and development. This investment supports the availability of our branded and generic medicines in over 150 countries, covering a wide range of therapeutic areas such as oncology, neuroscience, immuno-inflammatory diseases, and cardiovascular diseases.

What sets us apart at Servier is our commitment to working hand in hand with patients at every stage of the drug lifecycle. We are convinced that this close collaboration is essential to accelerate the development of tailored therapeutic solutions. In this regard, our teams are multiplying initiatives to actively involve patients and their associations, from the diagnostic phase to the use of treatments.

The strength of our patient engagement is illustrated by the success of the PatientView. Twelve international or European patient associations collaborated with Servier in 2023.

PatientView: a strong progress in our perception among patient organizations

We were ranked 14^th (up 12 places) based on the PatientView survey¹ on the reputation of pharmaceutical companies with patient organizations that work with us. We also moved up eight places to rank 20^th with patient organizations that know the Servier Group. In oncology, we are ranked 2^nd by the patient organizations that work with the Servier Group. These very good results highlight our commitment to working increasingly closely with patients and the patient organizations that represent them, particularly in oncology.

Innovative Initiatives

One of our flagship initiatives is the creation of the Patient Committee in Paris-Saclay, an innovative partnership bringing together 18 patients with different pathologies. The Servier Saclay Research & Development Patient Board was launched in November 2021 to inform patients, listen to their needs, and gather their ideas. It concluded at the end of 2023. A positive experience that leads our teams to reflect on the evolution of this Board, to better meet the needs of patients.

Five working groups were set up with Servier employees and patients covering different topics:

• Creation of a Patient Advisory Council to integrate the voice of patients throughout the life cycle of medicines within the Group’s therapeutic projects.
• Finding ways of visually representing patients at the R&D Institute in Paris-Saclay, with the aim of reflecting the impact of medical research on patients’ lives.
• Integration of patients within the start-up incubator Spartners in order to better engage patients in the start-up ecosystem.
• Decentralized trials: jointly developing decentralization guidelines that will apply to future clinical trials.
• Training program on patient engagement for Servier Group employees to incorporate patient engagement into our R&D projects.

However, our commitment is not limited to therapeutic innovation. Thus, at Servier, we are committed to successfully implementing initiatives co-created with and for patients.

---

¹ The PatientView 2022 survey was carried out with 2,207 patient organizations around the world. The findings concern 42 pharmaceutical groups in 27 different therapeutic areas.